|
Demidova T.Yu., Mkrtumyan A.M.
Review of current opportunities in cardiovascular risks management in patients with type 2 diabetes mellitus
|
№9 / 2021
|
|
Demidova T.Yu., Alekseeva Ya.G.
The place of sodium glucose co-transporter-2 inhibitors in the treatment of type 2 diabetes mellitus and its complications from the evidence-based medicine viewpoint
|
№8 / 2020
|
|
Vershinina M.V., Nechaeva G.I., Gudilin V.A.
Relative cardiovascular risk in young patients with connective tissue dysplasia
|
№6 / 2020
|
|
Murkamilov I.T., Aitbaev K.A., Fomin V.V., Murkamilova Zh.A., Rayimzhanov Z.R., Redjapova N.A., Yusupov F.A.
Braking progression of nephro- and cerebrovascular complications during atrial fibrillation: opportunities of rivaroxaban
|
№1 / 2020
|
|
Polyakova I.V., Borovkova N.Yu., Maslova T.I., Maksimova I.Yu., Zubova S.Yu., Solov’yanova E.N.
View of the vascular stiffness and cardiovascular risk in patients with chronic glomerulonephritis
|
№2 / 2019
|
|
A.P. Rebrov, M.A. Tyapkina, O.G. Karpova
Renal dysfunction and cardiovascular risk in rheumatic arthritis patients
|
№4 / 2018
|
|
I.I. Shaposhnik, I.I. Reznik
The use of statines in outpatient practice in high and very highrisk patients
|
№5 / 2017
|
|
I.M. Marusenko, I.I. Polskaya, T.I. Kulagina, N.N. Vezikova
Metabolic syndrome in patients with gout and its impact on the risk of cardiovascular diseases
|
№3 / 2016
|
Русский
